Contact
      Please use this form to send email to PR contact of this press release:
      
      TG Therapeutics and Jiangsu Hengrui Medicine Announce Global License Agreement for Development and Commercialization of Novel BTK Inhibitor Program for the Treatment of Hematologic Malignancies
    
      TO: